Storch H
Institut für Transfusionsmedizin Suhl, BRD.
Beitr Infusionsther. 1993;31:31-7.
The enormous progress made in biotechnology and purification of plasma proteins (pp) and the demands to avoid risks of transmitting HIV, hepatitis and other virus infections by these have resulted in the development of numerous recombinant human (rh) pp, which are now about to be used as replacement therapy in transfusion medicine. Human rh albumin has been used in clinical trials last year, a competition to serum albumin can be expected in the next time. During the last decade, the genes or cDNA have been cloned and characterized for all relevant pp involved in blood coagulation. Beside the rh factor VIII (rh FVIII) which has been introduced clinically in 1991, the rh FVIIa is under investigation in patients with hemophilia A and inhibitors. After establishing of rhFIX in triple transgenic mice, the industrial potential will be evaluated in terms of scale up culturing and production. The valuation of advantages and drawbacks of the current rh pp in comparison to conventional pp will have to be determined in the last decade of our century.
生物技术以及血浆蛋白（pp）纯化技术取得的巨大进展，加上避免通过这些物质传播艾滋病毒、肝炎及其他病毒感染风险的需求，促使了众多重组人（rh）血浆蛋白的研发，这些蛋白目前正准备用于输血医学的替代疗法。人重组白蛋白去年已用于临床试验，预计未来血清白蛋白将面临竞争。在过去十年中，参与血液凝固的所有相关血浆蛋白的基因或cDNA已被克隆和表征。除了1991年已临床应用的重组因子VIII（rh FVIII）外，重组因子VIIa（rh FVIIa）正在血友病A及有抑制剂的患者中进行研究。在三转基因小鼠中建立重组FIX（rhFIX）后，将根据扩大培养和生产来评估其工业潜力。在本世纪的最后十年，必须确定当前重组血浆蛋白与传统血浆蛋白相比的优缺点。
